Cruz C J, Aminoff M J, Meyerhoff D J, Graham S H, Weiner M W
Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, San Francisco, CA, USA.
Magn Reson Imaging. 1997;15(6):619-24. doi: 10.1016/s0730-725x(97)00079-9.
Assess the feasibility of proton MR spectroscopic imaging (1H-MRSI) of the striatum (putamen and caudate nucleus) in patients with Parkinson's disease and evaluate striatal neuronal density. Proton MRSI of the striatum and thalamus with 2 cc spatial resolution was performed in 10 patients with Parkinson's disease, 1 patient with atypical parkinsonism, and 13 control subjects. Single voxel proton MR spectra with signals from choline metabolites (Cho), creatine metabolites (Cr), and the putative neuronal marker, N-acetyl-aspartate (NAA), were obtained from the putamen and thalamus, but not the caudate nucleus, of patients with parkinsonism and control subjects. Metabolite rations in controls and patients were: in putamen NAA/Cho 1.70 +/- 0.25 vrs 1.74 +/- 0.32, NAA/Cr 2.80 +/- 0.79 vrs 2.36 +/- 0.42, Cho/Cr 1.63 +/- 0.25 vrs 1.39 +/- 0.3; in thalamus, NAA/Cho 1.78 +/- 0.15 vrs 1.62 +/- 0.22, NAA/Cr 2.78 +/- 0.34 vrs 2.64 +/- 0.41, Cho/Cr 1.57 +/- 0.25 vrs 1.65 +/- 0.28. There were no statistically significant differences between patients and controls. The putaminal NAA/Cho ratio of the single subject with atypical parkinsonism was lower than that of 9 of the 10 patients with classic Parkinson's disease and 11 of the 13 control subjects. Likewise, the putaminal NAA/Cr ratio in the single subject with atypical parkinsonism was lower than that of 7of the patients with guided selection of spectra from very small brain volumes, is a technique that can be used to evaluate neuronal density in individual subcortical gray nuclei in the brains of patients with parkinsonism. Using this technique, we have shown that Parkinson's disease produces no change in relative levels of the neuronal marker, NAA, in the putamen.
评估帕金森病患者纹状体（壳核和尾状核）质子磁共振波谱成像（1H-MRSI）的可行性，并评估纹状体神经元密度。对10例帕金森病患者、1例非典型帕金森综合征患者和13名对照者进行了空间分辨率为2cc的纹状体和丘脑质子MRSI检查。从帕金森综合征患者和对照者的壳核而非尾状核中获得了来自胆碱代谢物（Cho）、肌酸代谢物（Cr）以及假定的神经元标志物N-乙酰天门冬氨酸（NAA）信号的单体素质子磁共振波谱。对照组和患者的代谢物比率如下：壳核中，NAA/Cho为1.70±0.25对1.74±0.32，NAA/Cr为2.80±0.79对2.36±0.42，Cho/Cr为1.63±0.25对1.39±0.3；丘脑中，NAA/Cho为1.78±0.15对1.62±0.22，NAA/Cr为2.78±0.34对2.64±0.41，Cho/Cr为1.57±0.25对1.65±0.28。患者与对照者之间无统计学显著差异。非典型帕金森综合征单一受试者的壳核NAA/Cho比率低于10例经典帕金森病患者中的9例以及13名对照者中的11例。同样，非典型帕金森综合征单一受试者的壳核NAA/Cr比率低于7例帕金森病患者。从非常小的脑体积中引导选择光谱，是一种可用于评估帕金森综合征患者大脑中各个皮质下灰质核团神经元密度的技术。使用该技术，我们已表明帕金森病不会使壳核中神经元标志物NAA的相对水平发生变化。
